Sonnet BioTherapeutics (SONN)
(Delayed Data from NSDQ)
$1.04 USD
+0.04 (4.00%)
Updated Sep 19, 2024 04:00 PM ET
After-Market: $1.04 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
F Value D Growth D Momentum F VGM
Brokerage Reports
0 items in cart
Sonnet BioTherapeutics Holdings, Inc. [SONN]
Reports for Purchase
Showing records 1 - 8 ( 8 total )
Company: Sonnet BioTherapeutics Holdings, Inc.
Industry: Retail - Restaurants
Company: Sonnet BioTherapeutics Holdings, Inc.
Industry: Retail - Restaurants
FDA Greenlights IND for SON-1010 for Treatment of Advanced Solid Tumors; Phase 1 Study to Begin in 2Q 2022.
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Sonnet BioTherapeutics Holdings, Inc.
Industry: Retail - Restaurants
Preclinical Data Presentation at AACR Supports Expectations of Superior Anti-Tumor Efficacy of Bispecific IL-FHAB
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Sonnet BioTherapeutics Holdings, Inc.
Industry: Retail - Restaurants
Deep Dive on Engineered Cytokines; Using Modern Technology to Teach Old Dogs New Tricks
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Sonnet BioTherapeutics Holdings, Inc.
Industry: Retail - Restaurants
Sonnet Provides F1Q 2022 Earnings and Business Update; Clinical Trials for SON-1010 and SON-080 on Track for 2Q22 Launch
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Sonnet BioTherapeutics Holdings, Inc.
Industry: Retail - Restaurants
Sonnet Announces Results for FY2021; Signs Abound for Catalyst-Rich 2022 and Beyond.
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Sonnet BioTherapeutics Holdings, Inc.
Industry: Retail - Restaurants
We initiate with a Buy rating and $2 price target
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Sonnet BioTherapeutics Holdings, Inc.
Industry: Retail - Restaurants
|